392 related articles for article (PubMed ID: 34077627)
1. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
5. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
6. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
Sands BE; Han C; Gasink C; Jacobstein D; Szapary P; Gao LL; Lang Y; Targan S; Sandborn WJ; Feagan BG
J Crohns Colitis; 2018 Jul; 12(8):883-895. PubMed ID: 29726939
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
9. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Hanauer SB; Sandborn WJ; Feagan BG; Gasink C; Jacobstein D; Zou B; Johanns J; Adedokun OJ; Sands BE; Rutgeerts P; de Villiers WJS; Colombel JF; Ghosh S
J Crohns Colitis; 2020 Jan; 14(1):23-32. PubMed ID: 31158271
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
Louis EJ; Reinisch W; Schwartz DA; Löfberg R; Robinson AM; Berg S; Wang AW; Maa JF; Huang B; Pappalardo B
Adv Ther; 2018 Apr; 35(4):563-576. PubMed ID: 29516410
[TBL] [Abstract][Full Text] [Related]
11. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
[TBL] [Abstract][Full Text] [Related]
12. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
Narula N; Wong ECL; Dulai PS; Marshall JK; Colombel JF; Reinisch W
J Crohns Colitis; 2021 Mar; 15(3):462-470. PubMed ID: 32931556
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies.
Hibi T; Imai Y; Murata Y; Matsushima N; Zheng R; Gasink C
Intest Res; 2017 Oct; 15(4):475-486. PubMed ID: 29142515
[TBL] [Abstract][Full Text] [Related]
17. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease.
Rispo A; Scarpa R; Di Girolamo E; Cozzolino A; Lembo G; Atteno M; De Falco T; Lo Presti M; Castiglione F
Scand J Rheumatol; 2005; 34(5):387-91. PubMed ID: 16234187
[TBL] [Abstract][Full Text] [Related]
18. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
19. Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.
Wong ECL; Marshall JK; Reinisch W; Narula N
Inflamm Bowel Dis; 2021 May; 27(6):848-854. PubMed ID: 32812022
[TBL] [Abstract][Full Text] [Related]
20. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Sandborn WJ; Rebuck R; Wang Y; Zou B; Adedokun OJ; Gasink C; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG; Lynch JP
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):578-590.e4. PubMed ID: 33618023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
